Persistent pulmonary hypertension of the newborn with transposition of the great arteries: Successful treatment with bosentan

European Journal of Pediatrics

Volumn 167, Issue 4, 2008, Pages 437-440

  Goissen, C ^a   Ghyselen, L ^a   Tourneux, P ^a   Krim, G ^a   Storme, L ^b   Bou, P ^c   Maingourd, Y ^d  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Pharmacie Centrale   (France)

^d Cardiologie Pédiatrique ^*  (France)

Author keywords

Bosentan; Endothelin 1; Newborn; Persistent pulmonary hypertension of the newborn; Transposition of the great arteries

Indexed keywords

BOSENTAN; LIVER ENZYME; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL;

ABSENCE OF SIDE EFFECTS; ARTERY SURGERY; ARTICLE; CASE REPORT; COMORBIDITY; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GREAT VESSELS TRANSPOSITION; HUMAN; HYPOTENSION; MALE; NEWBORN; NEWBORN DISEASE; OXYGENATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; MALE; PULMONARY WEDGE PRESSURE; SULFONAMIDES; TRANSPOSITION OF GREAT VESSELS;

EID: 40049098028     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-007-0531-y     Document Type: Article

References (18)

1. Baquero H, Soliz A, Neira F, Venegas ME, Sola A (2006) Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 117:1077-1083
2. Barst R, Ivy D, Dingemanse J, Widlitz A, Schmidt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, vean Giersbergen P (2003) Pharmacokinetics, safety, and efficacity in pediatric patients with pulmonary arterial hypertension. Pharmacol Ther 73:372-382
3. Chang A, Wernovsky G, Kulik T, Jonas R, Wessel D (1991) Management of the neonate with transposition of the great arteries and persistent pulmonary hypertension. Am J Cardiol 68:1253-1255
4. Christou H, Adatia I, Van Marter L, Kane J, Thompson J, Stark A, Wessel D, Kourembanas S (1997) Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5′-monophosphate concentration in newborn infants with persistent pulmonary hypertension. J Pediatr 130:603-611
5. El-Sagaier M, Hellstrom-Westas L, Wettrell G (2005) Nitric oxide therapy in neonatal transposition of the great arteries. Acta Pediatrica 94:912-916
6. Endo A, Ayusawa M, Minato M, Takada M, Takahashi S, Harada K (2001) Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn. Eur J Pediatr 160:217-222
7. Galie N, Hinderliter A, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh S, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L (2003) Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41:1380-1386
8. Ivy D, Le Cras T, Horan M, Abman S (1998) Increased lung prepro ET-1 and decreased ETB-receptor gene expression in fetal pulmonary hypertension. Am J Physiol 274:L535-L541
9. Ivy D, Parker T, Kinsella J, Abman S (1998) Endothelin A receptor blockade decreases pulmonary vascular resistance in premature lambs with hyaline membrane disease. Pediatr Res 44:175-180
10. Ivy D, Parker T, Ziegler J, Galan H, Kinsella J, Tuder R, Abman S (1997) Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus. J Clin Inv 99:1179-1186
11. Ivy D, Ziegler J, Dubus M, Fox J, Kinsella J, Abman S (1996) Chronic intrauterine pulmonary hypertension alters endothelin receptor activity in the ovine fetal lung. Pediatr Res 39:435-442
12. Jaillard S, Belli E, Rakza T, Larrue B, Magnenant E, Rey C, Storme L (2005) Preoperative ECMO in transposition of the great arteries with persistent pulmonary hypertension. Ann Thorac Surg 79:2155-2158
13. Luciani G, Chang A, Starnes V (1996) Surgical repair of transposition of the great arteries in neonates with persistent pulmonary hypertension. Ann Thorac Surg 61:800-805
14. Newfeld E, Milton H, Muster A, Idriss F (1974) Pulmonary vascular disease in complete transposition of the great arteries: a study of 200 patients. Am J Cardiol 34:75-82
15. Rosenberg AA, Kennaugh J, Koppenhafer SL, Loomis M, Chatfield BA, Abman SH (1993) Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J Pediatr 123:109-114
16. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903
17. Walsh M, Stork E (2001) Persistent pulmonary hypertension of the newborn. Rational therapy bases on pathophysiology. Clin Perinatol 28:609-627
18. Williamson D, Wallman L, Jones R, Keogh A, Scroope F, Penny R, Weber C, Macdonald P (2000) Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 25:411-418